Geoffrey Parker serves as Executive Vice President and Chief Financial Officer at Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering allogeneic CAR T cell therapies to transform cancer treatment. Appointed in September 2020, Parker oversees all financial operations, including strategic planning, budgeting, investor relations, treasury, tax, and accounting functions. His leadership ensures robust financial discipline to support Allogene's advancing pipeline of investigational therapies targeting hematologic and solid tumors. With more than 25 years of experience in biotechnology and pharmaceuticals, Parker's career is marked by guiding companies through pivotal growth phases and transformative transactions. Prior to Allogene, he was CFO at Aduro Biotech from 2017 to 2020, managing finances amid clinical trials and major partnerships. Previously, as Vice President of Finance at Pharmacyclics, Inc., he played a instrumental role in the company's $21 billion acquisition by AbbVie in 2015, demonstrating his expertise in value creation and M&A execution. Parker's earlier roles include senior finance positions at Genentech (a Roche Group member) from 2006 to 2012, where he supported commercial operations and global finance, and as a consultant at Deloitte. His proven track record in scaling biotech finances, optimizing capital structures, and fostering investor confidence has been essential to Allogene's progress toward key clinical milestones and potential commercialization.